Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Glenmark launches triple-drug combo for type 2 diabetes
Glenmark Pharmaceuticals on Wednesday said it has launched a triple-fixed-dose combination (FDC) drug for treatment of diabetes. The Mumbai-based drug firm has introduced the combination of Teneligliptin, Dapagliflozin and Metformin under the brand name Zita.
It is indicated to improve glycemic control in patients with Type 2 diabetes.
Priced at Rs 14 per tablet (per day), the medication lowers the daily cost of therapy by 30 per cent; making it affordable for the patients, the drug firm stated.
Glenmark Pharma President & Business Head (India Formulations) Alok Malik said the drug helps improve the glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events.
According to IQVIA sales data for the 12-month period ending August 2023, the market for oral anti-diabetic drugs in India is estimated at Rs 12,522 crore, with an annual growth of 6.5 per cent against the corresponding period last year.